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Purpose: This study was conducted to perform a comparative analysis of the efficacy 
and safety of photoselective vaporization of the prostate (PVP) for treatment of benign 
prostatic hyperplasia (BPH) in men with a prostate volume greater than 60 cc.
Materials and Methods: The clinical data of 249 men with symptomatic BPH who under-
went PVP between January 2006 and June 2008 were retrospectively analyzed. All pa-
tients were classified into two groups according to their prostate volume (group A, ＜60 
cc; group B, ≥60 cc). The preoperative evaluation included a digital rectal exam, uri-
nalysis, prostate-specific antigen levels, International Prostate Symptom Score (IPSS), 
quality of life (QoL) score, maximal flow rate (Qmax), postvoid residual urine volume 
(PVR), and transrectal ultrasonography. The total operative time, used energy (kJ), 
urethral Foley catheter indwelling period, and the number of hospital days were re-
corded afterward. The IPSS, QoL score, Qmax, and PVR were evaluated at 1, 3, 6, and 
12 months postoperatively.
Results: In both groups, significant improvements in the subjective and objective void-
ing parameters were achieved and these improvements were sustainable for at least 
1 year with minimal complications. During the follow-up period, the PVR in group B 
significantly increased. Retrograde ejaculation and urethral stricture were the com-
mon complications in both groups. There was no significant difference in the incidence 
rate.
Conclusions: PVP is safe and efficacious, with durable results for men with sympto-
matic BPH and large prostate volumes.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is one of the most com-
mon diseases in men of middle age and over in Korea. Its 
importance and frequency are rapidly increasing as the re-
sult of increases in the elderly population, increases in the 
accessibility of westernized diets, increases in desires for 
improvements in quality of life, and other medical, social, 
and economical changes [1]. Treatment methods are also 
continuously changing. The early treatment chosen most 
often for BPH is pharmacotherapy, but it is not appropriate 
for some patients. When the side effects of pharmacother-
apy, such as dry mouth and orthostatic hypotension, are 
severe, patients may choose surgical treatment instead. 
Also, in cases accompanied by repetitive urinary tract ob-
struction, infection, bladder stone, renal failure, and gross 
hematuria, surgery is considered first rather than medical 
therapy [2]. Up to now, transurethral resection of the pros-
tate (TURP) was the standard surgical method [3], but 
TURP can have complications such as postoperative bleed-
ing, urethral stricture, urinary incontinence, retrograde 
ejaculation, and transurethral resection (TUR) syndrome. 
[4]. Photoselective vaporization of the prostate (PVP) by 
use of a laser was attempted as a minimally invasive treat-
ment in order to reduce these side effects. Recently, PVP 
using an 80 W potassium-titanyl-phosphate (KTP) laser or 
120 W lithium triborate (LBO) laser, which produces high 
energy, has been introduced and used. According to several Korean J Urol 2010;51:115-121
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studies, the treatment effects of PVP are similar to those 
of TURP. PVP was also reported to significantly reduce op-
eration time, hospitalization period, and urethral Foley 
catheter indwelling duration and to reduce complications 
by reducing the amount of bleeding [5-7]. However, addi-
tional studies on the application range of PVP are required. 
In particular, the operation time becomes longer and com-
plication rates increase after the operation compared with 
TURP if the prostate size is large. Enforcing PVP in this 
case is still controversial [8,9]. Still, because most previous 
studies dealt with patients with large prostates and ana-
lyzed the surgery results by comparison with TURP, it is 
not clear whether PVP results differ depending on prostate 
volume [6,8,10-13]. Therefore, in the present study, we div-
ided patients who underwent PVP at our hospital into 2 
groups: those with prostate volumes of less than 60 cc and 
those with volumes of 60 cc or greater. The two groups were 
compared in order to examine the utility and stability of 
PVP depending on prostate volume.
MATERIALS AND METHODS
A total of 249 patients with a chief complaint of lower uri-
nary tract obstruction due to BPH and who underwent PVP 
with an 80 W KTP laser or a 120 W LBO laser at two general 
hospitals from January 2006 to June 2008 were chosen as 
the subjects for this retrospective study. For comparison 
and analysis, the subjects were divided into group A, with 
prostate volumes of less than 60 cc, and group B, with pros-
tate volumes of 60 cc or more, on the basis of transrectal 
ultrasonography performed before surgery. All patients 
underwent history taking, physical examination, trans-
rectal ultrasonography, and a blood test for prostate-spe-
cific antigen (PSA) before surgery. Patients with palpable 
nodes on the digital rectal exam or with PSA levels over 4 
ng/ml before surgery underwent prostate tissue biopsy to 
confirm the existence of prostate cancer. Those diagnosed 
with prostate cancer were excluded from the study. 
Patients showing a neurogenic bladder in the urodynamic 
studies or those with urinary tract infection or urethral 
stricture were also excluded. Indications for surgery were 
an International Prostate Symptom Score (IPSS) of 12 
points or more before surgery and a maximal urinary flow 
rate (Qmax) lower than 15 ml/s, acute urinary tract ob-
struction, hydronephrosis or uremia, repetitive urinary 
tract infection due to excessive residual urine, bladder 
stone, and severe hematuria. Questionnaires to assess 
IPSS and quality of life (QoL) score and tests for examining 
Qmax and postvoid residual volume (PVR) were completed 
before surgery and 1, 3, 6, and 12 months after surgery. For 
the test items right after surgery, the total amount of en-
ergy used (kJ) and Foley catheter maintenance period were 
compared.
　The operation was done with monitored control anes-
thesia for all patients. Under the guide of videoendoscopy, 
a 22.5 Fr continuous flow cystoscope with a 30
o lens was 
used. An 80 W KTP laser or a 120 W LBO laser with a wave-
length of 532 nm was used through a 6 Fr side-deflecting 
optical fiber. Normal saline (0.9%) was used as the irrigat-
ing solution. The size and maintenance period of the ure-
thral Foley catheter applied after surgery were determined 
by considering the surgical findings and level of hematuria 
after surgery. Most patients had 20 Fr three-way Foley 
catheters, which were removed in the morning of the next 
day after surgery.
　Results for treatment effects were evaluated with IPSS, 
QoL score, Qmax, and PVR, whereas stability was eval-
uated through operation time, Foley catheter maintenance 
period after surgery, hospitalization period, urethral stric-
ture, and urinary tract infection. Statistical management 
was analyzed by using the Korean version of SPSS 12.0. 
Comparison between the two groups was done by Student’s 
t-test. Preoperative and postoperative baseline values of 
continuous variables were compared by paired t-test. 
Relationship with complications due to prostate volume 
was examined by using the chi-square test. Each statistical 
value was determined to have a significant difference when 
the p-value was less than 0.05.
RESULTS
1. Comparison of patients at baseline
Among 249 patients, 186 were designated as group A and 
63 as group B. The average age of group A was 67.2±7.5 
years, and that of group B was 69.4±6.7 years. Average 
prostate volume was 38.3±10.8 cc in group A and 78.6±15.4 
cc in group B. The PSA level of group A was 2.06±1.97 ng/ml 
and that of group B was 5.93±4.66 ng/ml. The average IPSS 
of patients before surgery was 20.2±7.3 for group A and 
19.1±8.3 for group B. The average QoL score of group A was 
4.5±1.9 and that of group B was 4.2±1.3. The average Qmax 
was 10.2±5.3 ml/s in group A and 11.1±6.0 ml/s in group 
B. The average PVR of group A was 73.3±92.0 ml and that 
of group B was 78.4±87.5 ml. Only prostate volume and 
PSA levels differed significantly between the two groups 
at baseline (Table 1).
2. Evaluation of treatment safety
A total of 128 (68.8%) patients among 168 patients of group 
A and 49 (77.8%) patients among 63 patients of group B un-
derwent PVP with the 80 W KTP laser. Other patients un-
derwent PVP with the 120 W LBO laser. The average oper-
ation time was 46.5±19.1 minutes for group A and 76.0± 
29.8 minutes for group B. The total amount of energy used 
was 122±80 kJ in group A and 200±89 kJ in group B. 
Operation time showed a statistically significant dif-
ference. The Foley catheter maintenance period after sur-
gery in group A was 24.4±15.2 hours and that in group B 
was 24.6±10.8 hours. Most of the patients removed their 
Foley catheters and were discharged without any other 
problems 1 day after surgery [156 (83.9%) in group A, 59 
(93.7%) in group B]. Foley catheters were reinserted in 20 
patients (10.8%) in group A and 3 patients (4.7%) in group 
B because of postoperative voiding difficulty. A total of 10 Korean J Urol 2010;51:115-121
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TABLE 1. Baseline characteristics of the patients (range) according to prostate size
Baseline characteristics Group A (n=186) Group B (n=63) 　p-value
Age
Prostate volume (cc)
Serum PSA (ng/ml)
IPSS 
QoL score
Qmax (ml/sec)
PVR (ml)
67.2±7.5 (44-87)
38.3±10.8 (14-59.5)
2.06±1.97 (0.1-11.6)
20.2±7.3 (2-35)
4.5±1.9 (1-7)
10.2±5.3 (2-42)
73.3±92.0 (0-620)
69.4±6.7 (57-88)
78.6±15.4 (60-122)
5.93±4.66 (1.1-21.2)
19.1±8.3 (3-3.5)
4.2±1.3 (1-7)
11.1±6.0 (3-30)
78.4±87.5 (0-513)
　0.464
　0.001
＜0.001
　0.270
　0.364
　0.185
　0.287
PSA: prostate-specific antigen, IPSS: International Prostate Symptom Score, QoL: quality of life, Qmax: maximal urinary flow rate,
PVR: postvoid residual volume, Group A: less than 60 ml, Group B: 60 ml or more
TABLE 2. Perioperative parameters (range), hospital courses, and postoperative complications according to prostate size
Group A (n=186) Group B (n=63) p-value
Perioperative parameters
　Operation time (minutes)
　Applied energy (kJ)
　Catheterization duration (hours)
　Postoperative admission duration (days)
Hospital courses
　Foley catheter reinsertion (n)
　Discharge with Foley catheter (n)
Postoperative complications
　Hematuria (%)
　Urethral stricture (%)
　Urinary tract infection (%)
　Urinary incontinence (%)
　Retrograde ejaculation (%)
　Erectile dysfunction (%)
46.5±19.1 (7-120)
122±80 (16-926)
24.4±15.2 (10-140) 
1.54±1.49 (0-15)
20 (10.8%)
10 (5.4%)
2 (1.1)
9 (4.8)
4 (2.2)
7 (3.8)
33 (17.8)
2 (1.1)
76.0±29.8 (25-170) 
200±89 (32-682)
24.6±10.8 (18-68)
1.71±1.33 (1-7)
3 (4.7%)
1 (1.6%)
2 (3.2)
3 (4.7)
1 (1.6)
1 (1.6)
9 (14.3)
1 (1.6)
＜0.001
0.314
0.515
0.462
0.056
0.066
0.252
0.980
0.783
0.397
0.527
0.747
Group A : less than 60 ml, Group B: 60 ml or more
TABLE 3. Perioperative parameters (range), hospital courses, and postoperative complications according to the laser instrument applied
80 W KTP (n=183) 120 W LBO (n=65) p-value
Perioperative parameters
　Operation time (minutes)
　Applied energy (kJ)
　Catheterization duration (hours)
　Postoperative admission duration (days)
Hospital courses
　Foley catheter reinsertion (n)
　Discharge with Foley catheter (n)
Postoperative complications
　Hematuria (%)
　Urethral stricture (%)
　Urinary tract infection (%)
　Urinary incontinence (%)
　Retrograde ejaculation (%)
　Erectile dysfunction (%)
50.5±21.4 (7-122)
152±90 (16-926)
25.1±14.9 (10-140)
1.50±0.53 (0-4)
16 (8.7%)
9 (4.9%)
3 (1.6)
10 (5.5)
3 (1.6)
6 (3.3)
32 (17.0)
2 (1.1)
43.0±20.2 (14-170) 
113±78 (18-328)
22.4±11.6 (12-78)
1.61±1.39 (1-15)
7 (11.0%)
2 (3.1%)
1 (1.5)
2 (3.1)
2 (3.1)
2 (3.1)
10 (15.0)
1 (1.5)
0.015
＜0.001
0.188
0.054
0.376
0.195
0.850
0.973
0.220
0.945
0.719
0.689
patients (5.4%) in group A and 1 patient (1.6%) in group B 
were discharged with their Foley catheter still inserted. 
However, there were no statistically significant differ-
ences between the two groups in the Foley catheter main-
tenance period, hospitalization period after surgery, or 
Foley catheter reinsertion rate.
　Concerning complications after surgery, in group A, 
there were 33 (17.8%) patients with retrograde ejaculation, 
9 (4.8%) with urethral strictures, 7 (3.8%) with urinary in-
continence, 4 (2.2%) with urinary tract infections, 2 (1.1%) Korean J Urol 2010;51:115-121
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FIG. 1. Postoperative follow-up outcome parameters of patients who underwent PVP according to prostate size. IPSS: International
Prostate Symptom Score, QoL: quality of life, Qmax: maximal urinary flow rate, PVR: postvoid residual volume, Group A: less than
60 ml, Group B: 60 ml or more, 
a: p＜0.01, 
b: p＜0.05, 
c: p=0.119.
with hematuria, and 2 patients (1.1%) with impotence. In 
group B, there were 9 patients (14.3%) with retrograde ejac-
ulation, 3 (4.7%) with urethral strictures, 2 (3.2%) with 
hematuria, 1 (1.6%) with urinary incontinence, 1 (1.6%) 
with urinary tract infection, and 1 (1.6%) with impotence. 
A total of 57 (30.6%) patients in group A and 17 (27.0%) pa-
tients in group B experienced complications. There were no 
significant differences between the two groups in the in-
cidences of total complications or in the incidence of each 
complication (Table 2). When all subjects were classified 
by the laser device used, the prostate volumes of both 
groups were similar (54.0±22.8 cc in the 80 W KTP laser 
group and 53.9±32.8 cc in the 120 W LBO laser group). 
Operation time and the amount of energy used were sig-
nificantly lower in the 120 W LBO laser group. However, 
no statistically significant differences were observed in 
preoperative or postoperative management or in complica-
tions after surgery (Table 3).
3. Comparison of treatment effects
Follow-up was done at 1, 3, 6, and 12 months after surgery 
of 152, 133, 100, and 63 patients in group A and of 52, 40, 
36, and 26 patients in group B, respectively. The IPSS was 
20.2 in group A before surgery and it decreased to 13.4, 10.8, 
10.5, and 10.7 at 1, 3, 6, and 12 months after surgery, 
respectively. The score in group B was 19.1 before surgery, 
and it decreased to 11.8, 8.7, 7.0, and 7.6 at 1, 3, 6, and 12 
months after surgery, respectively. The QoL score in group 
A was 4.5 before surgery and was reduced to 2.8, 2.3, 2.3, 
and 2.2 at 1, 3, 6, and 12 months after surgery, respectively. 
In group B, the QoL score was 4.2 before surgery and was 
reduced to 2.9, 2.1, 1.6, and 1.7 at 1, 3, 6, and 12 months 
after surgery, respectively. The Qmax of group A was 10.2 
ml/s before surgery and increased to 17.7, 17.7, 16.9, and 
15.7 ml/s each at 1, 3, 6, and 12 months after surgery, 
respectively. In group B, the Qmax was 11.1 ml/s and in-
creased to 18.7, 16.7, 15.6, and 16.0 ml/s at 1, 3, 6, and 12 
months after surgery, respectively. The PVR was 73.3 ml 
in group A before surgery and decreased to 24.6, 21.3, 20.8, 
and 21.8 ml at 1, 3, 6, and 12 months after surgery, 
respectively. In group B, the PVR was 78.4 ml before sur-
gery and decreased to 34.2, 37.3, 40.6, and 51.0 ml at 1, 3, 
6, and 12 months after surgery, respectively. The PVR 
seemed to increase significantly compared with pre-
operative test results until 12 months after surgery in both 
groups However, the PVR of group A was similar as time Korean J Urol 2010;51:115-121
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went by after surgery whereas that in group B increased 
as time went by. This difference was statistically signi-
ficant. In general, both groups showed a statistically sig-
nificant improvement in most of the objective and sub-
jective indexes related to treatment effects (Fig. 1).
DISCUSSION
The standard surgical treatment for BPH up until now has 
been TURP. However, TURP is associated with a risk of 
bleeding during surgery and complications such as TUR 
syndrome. The procedure requires a few days of Foley cath-
eter insertion and hospitalization even after surgery. 
Other complications such as hematuria, urinary tract ob-
struction, retrograde ejaculation, urethral stricture, and 
urinary incontinence may occur. Therefore, interest has re-
cently arisen in nonsurgical therapy and minimally in-
vasive treatment. Among these, endoscopic treatment us-
ing a laser is known to have treatment effects similar to 
those of TURP but with fewer side effects. Many studies 
have been done on this issue [5-7].
　The KTP and LBO lasers that are being commonly used 
at present all correspond to the green optical spectrum of 
532 nm. They are not easily absorbed in water but are very 
soluble in hemoglobin. Because they are absorbed in the 
red blood cells in tissues with abundant blood vessels such 
as the prostate, they show excellent tissue removal and he-
mostatic effects through evaporation [14]. Owing to these 
characteristics, PVP with lasers is associated with less 
bleeding during surgery than is TURP. It also secures a bet-
ter endoscopic view, less hematuria occurs after surgery, 
and the Foley catheter maintenance period can be mini-
mized. Reports continuously announce that the treatment 
effects of PVP are the same as after TURP [5-7].
　However, some controversy exists about the application 
range and side effects of PVP. In particular, these opinions 
arise in cases of large prostates. Horasanli et al conducted 
a prospective randomized comparison study of PVP and 
TURP among 76 patients with prostate volumes over 70 cc 
[8]. The group that received PVP showed a shorter period 
of Foley catheter maintenance and shorter hospitalization 
period than did the TURP group. However, operation time 
was longer and the patients showed less improvement in 
IPSS, Qmax, or PVR. Also, 7 patients (17.9%) among those 
who received PVP had to undergo surgery again. Thus, 
Horasanli et al reported than TURP was better than PVP 
in cases of large prostates. Sandhu et al, by contrast, con-
ducted a 1-year follow-up study of 64 patients with prostate 
volumes of more than 60 cc who received PVP [10]. At 1 year 
after surgery, Qmax increased from an average of 7.9 ml/s 
to 18.9 ml/s, PVR changed from 189 ml to 109 ml, and IPSS 
decreased from 18.4 to 6.7. Only one patient (2%) under-
went surgery again within 1 year. The study concluded that 
PVP was also an effective treatment method for large 
prostates.
　In Korea, Hwang et al reported treatment effects and 
complications of PVP depending on prostate volumes [9]. 
According to their study, there were no improvements in 
IPSS or QoL scores for prostates of 60 cc or more. The Foley 
catheter maintenance period was longer and urinary fre-
quency and urgency occurred more. Therefore, Hwang et 
al were opposed to enforcing PVP in patients with large 
prostates. Meanwhile, Choo et al conducted a 2-year fol-
low-up study after PVP in 104 patients [11]. When analyz-
ing the results by a prostate volume cutoff of 60 cc, 86 pa-
tients with volumes less than 60 cc showed an increase of 
Qmax from an average of 8.3 ml/s to 14.2 ml/s at 2 years 
after surgery. Their PVR decreased from 72.3 ml to 45.8 ml, 
IPSS from 22.6 to 9.9, and QoL scores from 4.4 to 2.3. 
Eighteen patients with prostate volumes of 60 cc or more 
showed an increase of Qmax from an average of 8.3 ml/s to 
15.5 ml/s, a decrease in the PVR from 128.4 ml to 71.9 ml, 
a decrease in IPSS from 21.5 to 9.7, and a decrease in QoL 
scores from 4.3 to 2.6 at 2 years after surgery. Our study 
also compared clinical indexes of IPSS, QoL score, Qmax, 
and PVR among patients with prostate volumes of less than 
60 cc or 60 cc or more. All of these indexes showed statisti-
cally meaningful improvement like that in cases with pros-
tate volumes less than 60 cc. We thus confirmed that PVP 
is an effective treatment for those with large prostates.
　Among the clinical indexes, PVR showed a statistically 
significant increase in both groups A and B when pre-
operative values were compared with values 12 months af-
ter surgery. However, the PVR in group A was similar after 
surgery, whereas that in group B increased as time went 
by. This difference was statistically significant. Even so, it 
is difficult to determine whether this was a general propen-
sity depending on prostate size because other urination in-
dexes did not differ significantly by time. Only 26 (41.3%) 
patients were followed up to 12 months. The possibility of 
their PVR being relatively more can be considered. Sandhu 
et al also confirmed that PVR increased at 12 months after 
surgery, but statistical significance was not mentioned 
[10]. More studies may be required to additionally analyze 
the relation of PVR with prostate volume.
　In this study, we observed a statistically significant dif-
ference in average operation time and the amount of energy 
used depending on prostate size. However, no statistically 
significant differences were seen in the Foley catheter 
maintenance period, hospitalization period, or Foley cath-
eter reinsertion between the two groups. This is the same 
result that Lee et al reported from a study of PVP results 
in 38 patients with prostate volumes of 40 cc or more [15]. 
Because 0.3-0.5 cc of prostate is evaporated per minute by 
PVP, the operation time and energy increased with pros-
tate volume. Meanwhile, bleeding did not increase in larger 
prostates owing to the excellent hemostatic effects of the 
KTP laser. Hematuria and urinary tract obstruction did 
not occur, so prostate volume was not considered to have 
a significant effect on the Foley catheter maintenance peri-
od, hospitalization period after surgery, or Foley catheter 
reinsertion.
　As for complications after surgery, retrograde ejacu-
lation and urinary stricture occurred the most but there Korean J Urol 2010;51:115-121
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were no statistically significant differences depending on 
prostate size. The incidence of retrograde ejaculation is be-
ing reported differently [5-13,15]. This may be because ret-
rograde ejaculation cannot be evaluated objectively and is 
recognized only when a doctor asks at the outpatient clinic 
or when the patient complains about his symptoms. Nine 
(4.8%) patients in the group with prostate volumes less 
than 60 cc and 3 patients (4.7%) in the group with prostate 
volumes of 60 cc or more had urethral stricture. All patients 
underwent endoscopic internal urethrotomy and are re-
ceiving follow-up at the outpatient clinic without any other 
problems. The incidence of urethral stricture after PVP is 
also reported differently in different studies [5-13,15]. This 
study is not any different from previous studies. However, 
whereas Hwang et al reported a high incidence of urethral 
strictures in patients with large prostates, it appeared that 
prostate volume did not affect the incidence of urethral 
strictures in our study [9]. Long-term, large-scale analysis 
and research may be required on this subject in the future.
　In the present study, we analyzed patients who under-
went PVP with an 80 W KTP laser or a 120 W LBO laser. 
The surgical devices and methods used were almost identi-
cal, and there were no differences in preoperative or post-
operative management. It may be difficult to understand 
why some items, including operation time, were completely 
the same because the output energy differed. However, we 
conclude that the final treatment results were identical be-
cause PVP with both lasers was carried out until an appro-
priate cavity was formed, like TURP, and analysis of stabil-
ity and usefulness could be done as well. The supply of 120 
W LBO lasers is increasing, so studies of only patients who 
received PVP with a 120 W LBO laser will become possible 
[7].
　Up until now, TURP was the gold standard for prostatic 
hypertrophy [3]. If long-term follow-up results with vari-
ous clinical data are sufficiently gathered instead of 
short-term results on PVP [16-18], we will be able to better 
evaluate the advantages and disadvantages of PVP com-
pared with TURP.
CONCLUSIONS
This study confirmed that PVP significantly improved both 
objective and subjective urination symptoms, even in pa-
tients with prostate volumes of 60 cc or more. Also, there 
were no statistically significant differences in hospital-
ization period, Foley catheter maintenance period, or com-
plications after surgery compared with those in patients 
with volumes less than 60 cc. More research on continuance 
of treatment effects and incidence of complications through 
long-term follow-up is required.
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